Table 1

Disease characteristics, previous treatments and ongoing treatments at the beginning of belimumab

Patients (n=50)
Disease characteristics at the start of belimumab
 SELENA-SLEDAI* score—median (range)6 (2–14)
 SELENA-SLEDAI score <42 (4)
 SELENA-SLEDAI score 4–731 (62)
 SELENA-SLEDAI score ≥817 (34)
 ≥1 BILAG† A or B score48 (96)
 PGA*— median (range)0.6 (0.4–1.5)
 Mild/moderate flare*41 (82)
 Severe flare*8 (16)
 SDI score‡—median (range)0 (0–3)
 Positive Farr assay20 (40)
 Low C315 (30)
Previous treatments
 Number of drugs used per patient, median (range)4 (2–9)
 HCQ49 (98)
 Chloroquine5 (10)
 Prednisone49 (98)
 Methotrexate38 (76)
 MMF or MPA9 (18)
 Azathioprine10 (20)
 Rituximab3 (6)
 Thalidomide5 (10)
 Leflunomide1 (2)
 Colchicine3 (6)
 Topical tacrolimus6 (12)
Ongoing treatments at the start of belimumab
 Hydroxychloroquine45 (90)
  Patients with (HCQ)>750 ng/mL§38/45 (84)
 Prednisone45 (90)
  Prednisone dose—mg/day, median (range)10 (4–50)
  Increase¶ of corticosteroids16 (32)
  Increase of daily prednisone13 (26)
  Intravenous high-dose methylprednisolone9 (18)
 Methotrexate30 (60)
 MMF or MPA5 (10)
 Azathioprine4 (8)
 Colchicine3 (6)
 Thalidomide2 (4)
 Chloroquine2 (4)
 Leflunomide1 (2)
 Topical tacrolimus1 (2)
  • Values are expressed as, n (%), unless stated otherwise.

  • (HCQ), HCQ blood concentration.

  • *Defined using Petri et al.9

  • †Defined using Isenberg et al.7

  • ‡Defined using Gladman et al.10

  • §Considered to be the therapeutic target.

  • ¶Defined as an increase of daily prednisone and/or intravenous high dose (>250 mg) methylprednisolone infusion between day 0 (the day of the start of belimumab) and month 1.

  • BILAG, British Isles Lupus Assessment Group; C3, complement fraction 3; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MPA, mycophenolic acid; PGA, physician’s global assessment; SDI, SLICC Damage Index; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.